Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Business revenue reflects receipts from analytical services and other sources. The losses were primarily attributable to the continuation of basic and drug-discovery research, research and development expenses associated with progress in clinical development in the 3 areas, and the recording of cost of sales in the cancer precision medicine-related business.
Although conditions exist that raise significant doubt regarding the going concern assumption, the Company has ¥2,326 million in cash and deposits and has determined that no material uncertainty exists. There are no applicable matters to disclose in the notes on the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥170,766 thousand |
| Operating profit | ¥-285,140 thousand |
| Ordinary income | ¥-287,642 thousand |
| Profit attributable to owners of the parent | ¥-288,935 thousand |
| Total assets | ¥2,612,932 thousand |
| Net assets | ¥2,348,414 thousand |
| Cash and cash equivalents at end of period | ¥2,326,240 thousand |
| Segment revenue | Segment Pharmaceutical research and development and related businesses / Net Sales ¥1,981 thousand / Year on year against the same period last year Decrease of ¥0 million, Segment Cancer precision medicine-related business / Net Sales ¥168,785 thousand / Year on year against the same period last year Decrease of ¥30 million |
| Segment profit | Segment Pharmaceutical research and development and related businesses / Segment profit ¥-160,925 thousand / Prior-year period ¥-179,705 thousand / Year on year against the same period last year Not disclosed, Segment Cancer precision medicine-related business / Segment profit ¥-17,118 thousand / Prior-year period ¥-21,206 thousand / Year on year against the same period last year Not disclosed |
| Impairment loss | ¥1,302 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of subscription rights to shares ¥550 thousand / Extraordinary loss Impairment Losses ¥1,302 thousand |
| Disclosure regarding the going concern assumption | Although conditions exist that raise significant doubt regarding the going concern assumption, the Company has ¥2,326 million in cash and deposits and has determined that no material uncertainty exists. There are no applicable matters to disclose in the notes on the going concern assumption. |
| Factors Behind Changes in Business Performance | Business revenue reflects receipts from analytical services and other sources. The losses were primarily attributable to the continuation of basic and drug-discovery research, research and development expenses associated with progress in clinical development in the 3 areas, and the recording of cost of sales in the cancer precision medicine-related business. |
Items this document does not state (21)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Business revenue reflects receipts from analytical services and other sources. The losses were primarily attributable to the continuation of basic and drug-discovery research on drug candidate compounds, progress in clinical development in the 3 areas of small-molecule drugs, cancer peptide vaccines and antibody drugs, and the recording of cost of sales in the cancer precision medicine-related business.